Pitt Street Research has published a 27-page overview report on Imagion Biosystems, Limited. This detailed report includes close examinations of the company’s business and investment potential, including:

• Introducing Imagion Biosystems
• Ten reasons to look at Imagion
• MagSense is bridging the gap between traditional imaging and newer screening technologies
• MagSense’s HER2 imaging agent de-risks and accelerates the commercialisation path
• Expansion of MagSense technology across other cancer types with a high unmet medical need
• The MagSense product pipeline is set to tap major markets of cancer diagnostics
• Success in securing growth funding is another critical milestone Valuing Imagion
• Key risks facing Imagion
• Imagion has a strong management team
• Companies to watch
• Appendix I – Glossary
• Appendix II – Capital structure
• Appendix III – IP position
• Appendix IV – Papers relevant to Imagion
• Appendix V – Analyst qualifications

View the full market research report HERE >

Questions about this announcement or other investor-related inquiries? Please email our investor relations department at: investor@imagionbio.com.